A Two-Week, Randomised, Double-Blind Study Assessing the Onset of Effect Questionnaire Administered Pre-Dose Versus Post-Dose in Adult Subjects (greater than or equal to 18 years) With Mild to Moderate Asthma, Receiving SYMBICORT pMDI [pressurised metered-dose inhaler] 80/4.5 microg x 2 Actuations Twice Daily or Budesonide HFA [hydrofluoroalkane] pMDI 80 microg x 2 Act. Twice Daily.

Trial Profile

A Two-Week, Randomised, Double-Blind Study Assessing the Onset of Effect Questionnaire Administered Pre-Dose Versus Post-Dose in Adult Subjects (greater than or equal to 18 years) With Mild to Moderate Asthma, Receiving SYMBICORT pMDI [pressurised metered-dose inhaler] 80/4.5 microg x 2 Actuations Twice Daily or Budesonide HFA [hydrofluoroalkane] pMDI 80 microg x 2 Act. Twice Daily.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2009

At a glance

  • Drugs Budesonide; Budesonide/formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Apr 2009 Actual patient number (134) added as reported by ClinicalTrials.gov record (NCT00449501).
    • 11 Jan 2008 Status changed from in progress to completed.
    • 12 Oct 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top